1625 related articles for article (PubMed ID: 19792990)
1. Clinical and economic outcomes of rabbit antithymocyte globulin induction in adults who received kidney transplants from living unrelated donors and received cyclosporine-based immunosuppression.
Miller JT; Collins CD; Stuckey LJ; Luan FL; Englesbe MJ; Magee JC; Park JM
Pharmacotherapy; 2009 Oct; 29(10):1166-74. PubMed ID: 19792990
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of extended-duration inpatient-to-outpatient rabbit antithymocyte globulin induction in de novo kidney transplant recipients: 6-month outcomes.
Trofe-Clark J; Reese PP; Patel HJ; Jakobowski D; Goral S; Doll SL; Abt PL; Bloom RD
Transplantation; 2012 Sep; 94(5):506-12. PubMed ID: 22895613
[TBL] [Abstract][Full Text] [Related]
3. Sequential biological immunosuppression. Induction therapy with rabbit antithymocyte globulin.
Guttmann RD; Flemming C
Clin Transplant; 1997 Jun; 11(3):185-92. PubMed ID: 9193840
[TBL] [Abstract][Full Text] [Related]
4. Outcome of cadaveric renal transplantation by induction treatment in the cyclosporine era.
Hariharan S; Alexander JW; Schroeder TJ; First MR
Clin Transplant; 1996 Apr; 10(2):186-90. PubMed ID: 8664516
[TBL] [Abstract][Full Text] [Related]
5. Rabbit antithymocyte globulin is more beneficial in standard kidney than in extended donor recipients.
Hardinger KL; Brennan DC; Schnitzler MA
Transplantation; 2009 May; 87(9):1372-6. PubMed ID: 19424038
[TBL] [Abstract][Full Text] [Related]
6. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
Uslu A; Nart A; Taşli FA; Postaci H; Aykas A; Doğan M; Sahin T
Nephrology (Carlton); 2008 Feb; 13(1):80-6. PubMed ID: 18199109
[TBL] [Abstract][Full Text] [Related]
7. 20-year follow-up results of a randomized controlled trial comparing antilymphocyte globulin induction to no induction in renal transplant patients.
Cantarovich M; Durrbach A; Hiesse C; Ladouceur M; Benoit G; Charpentier B
Transplantation; 2008 Dec; 86(12):1732-7. PubMed ID: 19104413
[TBL] [Abstract][Full Text] [Related]
8. Comparison of induction based on continuous vs discontinuous administration of antithymocyte globulins in renal transplant patients: efficacy and long-term safety.
Esposito L; Kamar N; Durand D; Rostaing L
Transplant Proc; 2005 Mar; 37(2):892-4. PubMed ID: 15848567
[TBL] [Abstract][Full Text] [Related]
9. Living donor kidney transplantation across positive crossmatch: the University of Illinois at Chicago experience.
Thielke JJ; West-Thielke PM; Herren HL; Bareato U; Ommert T; Vidanovic V; Campbell-Lee SA; Tzvetanov IG; Sankary HN; Kaplan B; Benedetti E; Oberholzer J
Transplantation; 2009 Jan; 87(2):268-73. PubMed ID: 19155983
[TBL] [Abstract][Full Text] [Related]
10. Clinical and economic analysis of delayed administration of antithymocyte globulin for induction therapy in kidney transplantation.
McGillicuddy JW; Taber DJ; Pilch NA; Kohout RK; Bratton CF; Chavin KD; Baliga PK
Prog Transplant; 2013 Mar; 23(1):33-8. PubMed ID: 23448818
[TBL] [Abstract][Full Text] [Related]
11. Prevention of acute rejection with antithymocyte globulin (Thymoglobuline): its potential to reduce corticosteroids.
Cantarovich D
J Nephrol; 2004; 17 Suppl 8():S40-6. PubMed ID: 15599885
[TBL] [Abstract][Full Text] [Related]
12. Induction versus noninduction therapy in kidney transplantation: considering different PRA levels and different induction therapies.
Castro MC; Araujo LM; Nahas WC; Arap S; David-Neto E; Ianhez LE
Transplant Proc; 2004 May; 36(4):874-6. PubMed ID: 15194299
[TBL] [Abstract][Full Text] [Related]
13. Cadaveric kidney transplantation under prophylactic polyclonal antibody immunosuppression with anti-lymphoblast globulin versus anti-thymocyte globulin.
Indudhara R; Novick AC; Hodge E; Goormastic M; Papajcik D; Mastroianni B; Cook D
Urology; 1996 Jun; 47(6):807-12. PubMed ID: 8677568
[TBL] [Abstract][Full Text] [Related]
14. One center's experience with antithymocyte globulin treatment for acute rejection in renal transplantation.
Colak T; Sevmiş S; Karakayali H; Moray G; Haberal M
Transplant Proc; 2008; 40(1):123-5. PubMed ID: 18261564
[TBL] [Abstract][Full Text] [Related]
15. Neoquadruple induction with antithymocyte globulin/azathioprine/cyclosporine/prednisolone in simultaneous pancreas and kidney transplant recipients: 8.5-year results.
Schulz T; Kapischke M; Busing M
Transplant Proc; 2005 May; 37(4):1815-7. PubMed ID: 15919475
[TBL] [Abstract][Full Text] [Related]
16. Kidney transplantation from living donors: comparison of results between related and unrelated donor transplants under new immunosuppressive protocols.
Chkhotua AB; Klein T; Shabtai EL; Yussim A; Bar-Nathan N; Shaharabani E; Lustig S; Mor E
Isr Med Assoc J; 2003 Sep; 5(9):622-5. PubMed ID: 14509149
[TBL] [Abstract][Full Text] [Related]
17. [Living-donor kidney transplantation in the cyclosporine era].
Campise M; Tarantino A; Berardinelli L; Finazzi S; Montagnino G; Rossini G; Scalamogna M; Cesana B; Ponticelli C
G Ital Nefrol; 2002; 19(1):49-54. PubMed ID: 12165946
[TBL] [Abstract][Full Text] [Related]
18. One year results of preoperative single bolus ATG-Fresenius induction therapy in sensitized renal transplant recipients.
Wang D; Chen JH; Wu WZ; Yang SL; Wu GJ; Wang H; Tan JM
Transplant Proc; 2007; 39(1):69-72. PubMed ID: 17275476
[TBL] [Abstract][Full Text] [Related]
19. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin.
Mai ML; Ahsan N; Wadei HM; Genco PV; Geiger XJ; Willingham DL; Taner CB; Hewitt WR; Grewal HP; Nguyen JH; Hughes CB; Gonwa TA
Transplantation; 2009 Jan; 87(2):227-32. PubMed ID: 19155977
[TBL] [Abstract][Full Text] [Related]
20. Reduced dose rabbit anti-thymocyte globulin induction for prevention of acute rejection in high-risk kidney transplant recipients.
Klem P; Cooper JE; Weiss AS; Gralla J; Owen P; Chan L; Wiseman AC
Transplantation; 2009 Oct; 88(7):891-6. PubMed ID: 19935460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
